Status:
COMPLETED
Neuromuscular Control in Individuals Following ACL-Reconstruction
Lead Sponsor:
University of Virginia
Conditions:
Anterior Cruciate Ligament Injuries
Quadriceps Muscle Atrophy
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The purpose of this study is to investigate the neurophysiological contributors to muscle function following ACL Reconstruction and the influence of motor control biofeedback exercise on measures of m...
Detailed Description
1. Pre-treatment neuromuscular assessment Cortical Active Motor Threshed We will measure motor evoked potentials with the use of a Transcranial magnetic stimulator (MagStim model 200, Magstim Co., Ltd...
Eligibility Criteria
Inclusion
- • Ages 18-45
- At the time point of return to play progression following ACL Reconstruction
- Physically active individuals based on current ACSM guidelines of 30 minutes of moderate-intensity daily physical activity three days a week)
Exclusion
- Subjects who are known to be pregnant (self-reported)
- Subjects diagnosed with malignancy
- Subjects with serious infection near the lower limb
- Subjects with known muscular abnormalities
- History of cardiopulmonary disorder
- Subjects with a previous history of stroke
- History of neurological or psychiatric disorders including poorly controlled migraine headaches, seizure disorder, history or immediate family history of seizures and/or epilepsy
- Subjects with any type of neuropathy (numbness and tingling)
- Subjects with a clinical diagnosis of multiple sclerosis (MS) or Parkinson's Disease
- Implanted biomedical device (active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, and vagus nerve stimulators)
- History of skull fracture
- Subjects who have any metal implants anywhere in their head, neck or shoulders
- Patients taking any medications, which may influence cortical excitability, which could influence neurophysiologic measures) and affect objective clinical data (e.g. antispastics, anxiolytics, hypnotics, ant-epileptics)
- Subjects who are prescribed medications which may influence cortical excitability, which could influence neurophysiologic measures) and affect objective clinical data (e.g. antispastics, anxiolytics, hypnotics, ant-epileptics), will not be able to remain in the study.
- Unable to provide consent.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04495075
Start Date
March 1 2019
End Date
March 1 2020
Last Update
July 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia
Charlottesville, Virginia, United States, 22903